Mr. Lim Kim Hai was appointed the Chairman of Lynk Biotechnologies
in June 2005. Mr. Lim, based in Singapore, has been awarded two scholarships
by the Singapore government. The first was to complete an undergraduate cum
Masters degree in electronics engineering in the prestigious French 'Grande Ecole'
schools of engineering. The second was awarded while he was serving with the
Ministry of Defence of Singapore to complete a Masters in Public Administration
at the elite Ecole Nationale d’ Administration of France. After a period of
10 years as a Defence Specialist Engineer, Mr. Lim left the civil service to
start his own businesses. Mr. Lim currently has an extensive portfolio of investment
and has business interests in many countries. He is the Executive Chairman of
Regional Express, Australia’s largest listed regional airline, and is also Chairman
of WooWorld Pte Ltd which is a supplier of online and mobile games to telecommunication
companies in China, Japan and South East Asia.
Mr. Lee Thian Soo is the alternate director to Mr. Lim
Kim Hai. He has extensive international business experience and currently
is the Chairman and owner of several businesses with subsidiaries in South
East Asia. These include an aviation components and service company, specialising
in military aircraft, as well as a medical equipment supply company, involved
in the distribution and marketing of medical equipment and drugs. He is
also on the board of a mobile/internet gaming company as well as Regional
Express, Australia’s largest listed regional airline.
Dr. Tan Boon Tiong is the Executive Director of Lynk Biotechnologies.
Dr. Tan has wide-ranging experience in the telecommunications and information
technology industries. While at SingTel from 1996 to 2000, he headed
the technology development department. He later joined Mediacorp Singapore
in 2000 where he managed a S$100 million technology fund and led in Mediacorp's
efforts in developing its New Media business. From 2004 to 2006, Dr.
Tan was the Director, National University of Singapore Venture Support where
he spearheaded the funding and incubation of technology start-ups from NUS. Dr.
Tan holds a Ph.D. from Cambridge University.
Dr. Lee Chee Wee is the Founder and Scientific Advisor of Lynk Biotechnologies Pte Ltd and has over twenty years of experience in drug discovery and development processes. He received his B.Sc. and M.Sc. from McGill University, Canada, and his Ph.D. from the University of Alberta, Canada. He was also a recipient of the Alberta Heritage Foundation Scholarship for Medical Research (AHFMR). Dr Lee had carried out his Post-doctoral Fellowship at Yale Comprehensive Cancer Centre and Department of Pharmacology at Yale University School of Medicine, USA before pursuing his academic career at the Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, where he is currently an Adjunct Associate Professor. He also serves as an academic advisor to various Life Science companies, and is a founding member and Vice President of the Singapore Fellowship of Inventors (FOI). Dr Lee is currently a Director at the School of Applied Science, Temasek Polytechnic, and the Intellectual Property Office of Singapore (IPOS).
Dr. Gurinder Shahi is currently the Chairman of BioEnterprise
Asia, and Director of the Global BioBusiness Initiative at the Marshall
School of Business, University of Southern California. Dr. Shahi is a
physician with training in molecular biochemistry and international health
policy and management. He is a leading expert on change management and
strategic program implementation in healthcare, the life sciences, and
biotechnology. His experience includes work on life science technology
assessment; strategic business planning; R&D and work process improvement;
performance appraisal of joint ventures and strategic alliances; market
strategy development; economic and policy analysis for health intervention;
and evidence-based decision-making for investment and implementation.
Dr. Shahi played a key role in the development of several major international initiatives including the International Vaccine Institute and the Asia-Pacific International Molecular Biology Network (for which he served as Executive Director/Coordinator), and had served as an advisor and consultant to leading international organizations, governments, corporations and foundations. He has authored over 50 articles, referred journal papers and conference presentations. He is the author of the influential book "BioBusiness in Asia" (Pearson Prentice Hall, 2004) and served as lead editor for "International Perspectives on Environment, Development and Health: Toward a Sustainable World" (GS Shahi, BS Levy, A Binger, T Kjellstrom and RS Lawrence, Springer Publishing Company, New York, 1997). He earned an M.D. and Ph.D, from the National University of Singapore; and an M.P.H. from Harvard University.
Dr. Shahi played a key role in the development of several major international initiatives including the International Vaccine Institute and the Asia-Pacific International Molecular Biology Network (for which he served as Executive Director/Coordinator), and had served as an advisor and consultant to leading international organizations, governments, corporations and foundations. He has authored over 50 articles, referred journal papers and conference presentations. He is the author of the influential book "BioBusiness in Asia" (Pearson Prentice Hall, 2004) and served as lead editor for "International Perspectives on Environment, Development and Health: Toward a Sustainable World" (GS Shahi, BS Levy, A Binger, T Kjellstrom and RS Lawrence, Springer Publishing Company, New York, 1997). He earned an M.D. and Ph.D, from the National University of Singapore; and an M.P.H. from Harvard University.